Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DLBS3233
- Development stage
- Phase 3
- Lead developer
- Dexa Medica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DLBS3233 is a standardized bioactive fraction derived from two Indonesian plants, Cinnamomum burmanii and Lagerstroemia speciosa. It is developed as an insulin sensitizer for the treatment of type 2 diabetes mellitus and polycystic ovary syndrome (PCOS). The extract acts primarily by enhancing insulin signal transduction, increasing the expression of genes involved in glucose uptake and insulin sensitivity such as peroxisome proliferator-activated receptor gamma (PPARγ), phosphatidylinositol 3 kinase (PI3K), Akt, and glucose transporter 4 (GLUT4). It also stimulates adiponectin production and modulates lipoprotein metabolism. Clinical studies have shown that DLBS3233 improves insulin resistance, glycemic control, lipid profile, β-cell performance, and is well tolerated with a low risk of hypoglycemia[1][2][5][8]. The drug was developed using patented extraction technology.
- Brand names
- Inlacin
- Other names
- Cinnamomum burmannii and Lagerstroemia speciosa extract
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)PPARG (Peroxisome proliferator-activated receptor gamma)AdipoR (Adiponectin receptor)PIK3CA (Phosphoinositide 3-kinase alpha)AKT (RAC-alpha serine/threonine-protein kinase)
Beyond the preview
Go deeper on DLBS3233.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DLBS3233.